Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Sold by BNP PARIBAS ASSET MANAGEMENT Holding S.A.

BNP PARIBAS ASSET MANAGEMENT Holding S.A. trimmed its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 0.5% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 907,044 shares of the biopharmaceutical company’s stock after selling 4,131 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A.’s holdings in Agios Pharmaceuticals were worth $40,300,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Acadian Asset Management LLC acquired a new stake in shares of Agios Pharmaceuticals in the 2nd quarter worth $37,000. Quest Partners LLC acquired a new stake in Agios Pharmaceuticals in the second quarter valued at about $40,000. Mirae Asset Global Investments Co. Ltd. lifted its position in Agios Pharmaceuticals by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 363 shares during the period. CWM LLC boosted its holdings in Agios Pharmaceuticals by 554.7% in the 3rd quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $96,000 after purchasing an additional 1,836 shares in the last quarter. Finally, North Star Asset Management Inc. acquired a new position in Agios Pharmaceuticals during the 2nd quarter worth approximately $216,000.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, CFO Cecilia Jones sold 2,542 shares of the stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $49.03, for a total value of $124,634.26. Following the sale, the chief financial officer now directly owns 20,158 shares in the company, valued at $988,346.74. This represents a 11.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.93% of the stock is currently owned by insiders.

Agios Pharmaceuticals Stock Up 1.7 %

Shares of AGIO stock opened at $55.54 on Friday. Agios Pharmaceuticals, Inc. has a fifty-two week low of $20.96 and a fifty-two week high of $62.58. The business has a fifty day simple moving average of $47.24 and a 200-day simple moving average of $44.36. The stock has a market cap of $3.17 billion, a P/E ratio of 4.89 and a beta of 0.75.

Wall Street Analysts Forecast Growth

AGIO has been the subject of several recent analyst reports. Raymond James reissued an “outperform” rating and issued a $51.00 price target on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Scotiabank raised their target price on Agios Pharmaceuticals from $51.00 to $53.00 and gave the company a “sector outperform” rating in a report on Friday, November 1st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Friday, September 20th. Leerink Partnrs cut shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 27th. Finally, StockNews.com raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 9th. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $52.33.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.